Page 4,904«..1020..4,9034,9044,9054,906..4,9104,920..»

Orillia native receives medical treatment in Georgia

Posted: Published on September 17th, 2013

ORILLIA- Andrew Parks had started to believe he wasnt going to get better. After months of literally sitting alone in the dark, the 21-year-old Orillia native, who suffered a serious blow to the head during a hockey game in September 2012, was questioning if it was how he was going to be living the rest of his life. You dont think its ever going to be any different, Parks said, a huge smile on his face as he shared the story of his recovery. After six long months and little to no improvement in his condition, Parks was admitted to the Carrick Brain Center in Marietta, Ga. the same one where NHL superstar Sidney Crosby received treatment in 2011 to which he credits a large portion, if not all, of his recovery. Its like I never had a concussion, said Parks, who has moved to New York state, where hes playing hockey for Brockport University this fall. Parks, a forward with the Trenton Golden Hawks Junior 'A' hockey team, was hit from behind and driven head first into the boards last year during an early regular-season game against the Kingston Voyageurs. Other than the fact his neck was sore, he … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Orillia native receives medical treatment in Georgia

European Commission OKs Genzyme's Multiple Sclerosis Treatment Lemtrada

Posted: Published on September 17th, 2013

By RTT News, September 17, 2013, 01:20:00 AM EDT (RTTNews.com) - Genzyme, a Sanofi company (SNYNF, SNY) reported that the European Commission has granted marketing authorization for its multiple sclerosis treatment, Lemtrada, following the August 30th approval of Aubagio. Both the products are being planned to launch in the EU soon. Lemtrada is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis or RRMS with active disease defined by clinical or imaging features. Lemtrada 12 mg has a novel dosing and administration schedule of two annual treatment courses. The first treatment course of Lemtrada is administered through intravenous infusion on five consecutive days, while the second course is administered on three consecutive days, a year later. The Lemtrada clinical development program included two pivotal randomized Phase III trials comparing treatment with Lemtrada to high-dose subcutaneous interferon beta-1a in patients with RRMS who had active disease and were either new to treatment (CARE-MS I) or who had relapsed while on prior therapy (CARE-MS II), as well as an ongoing extension study. According to the company, in CARE-MS I, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates; the difference observed in slowing disability progression … Continue reading →

Posted in MS Treatment | Comments Off on European Commission OKs Genzyme's Multiple Sclerosis Treatment Lemtrada

European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada™ (alemtuzumab)

Posted: Published on September 17th, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY) announced today that the European Commission has granted marketing authorization for Lemtrada. This follows the August 30th approval of Aubagio. The company intends to begin launching both products in the EU soon. The approvals of Lemtrada and Aubagio in the European Union represent an important milestone for Genzyme and demonstrate our focus on scientific innovation and commitment to multiple sclerosis patients, said Genzyme CEO and President, David Meeker, M.D. This is particularly exciting as the EU approval is the first for Lemtrada globally. We look forward to making these unique therapies available to MS patients very soon. Lemtrada is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features. Lemtrada 12 mg has a novel dosing and administration schedule of two annual treatment courses. The first treatment course of Lemtrada is administered via intravenous infusion on five consecutive days, and the second course is administered on three consecutive days, 12 months later. The Lemtrada clinical development program included two pivotal randomized Phase III studies comparing treatment with Lemtrada to high-dose subcutaneous interferon beta-1a (Rebif) in patients with RRMS … Continue reading →

Posted in MS Treatment | Comments Off on European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada™ (alemtuzumab)

Genzyme’s MS drug Lemtrada wins approval from European regulators

Posted: Published on September 17th, 2013

Genzyme, now a Cambridge-based unit of the French drug giant Sanofi, said that regulators have given it approval to market a multiple sclerosis drug in the European Union. The drug is called Lemtrada, and it is one that Genzyme has high hopes for. Genzyme has a heritage in developing drugs for rare diseases. Now it is also looking to be a presence in the MS space, which analysts have estimated to be a $13 billion market. Another Massachusetts company, Biogen Idec, is already a major player in MS drugs. In a press release, Genzyme said Lemtrada has been indicated for the treatment of adult patients with relapsing remitting multiple sclerosis. A few weeks ago, European regulators granted approval to Aubagio, another Genzyme MS drug. MS, a disease estimated to affect more than 2.1 million people globally, is said to require highly individualized treatment approaches. Genzyme said it intends to begin launching both products in the European Union soon. The approvals of Lemtrada and Aubagio in the European Union represent an important milestone for Genzyme and demonstrate our focus on scientific innovation and commitment to multiple sclerosis patients,Genzyme chief executive and president David Meeker, MD, said in a statement.This is particularly … Continue reading →

Posted in MS Treatment | Comments Off on Genzyme’s MS drug Lemtrada wins approval from European regulators

Sanofi wins EU approval for second MS treatment

Posted: Published on September 17th, 2013

Home Mail News Sports Finance Weather Games Groups Answers Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Mobile Yahoo! News Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo! Home Video Photos GMA Year in Review Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Sideshow Katie's Take Power Players This Could Be Big Newsmakers Trending Now The Upbeat Who Knew? Nightline Fix … Continue reading →

Posted in MS Treatment | Comments Off on Sanofi wins EU approval for second MS treatment

The Fight against Familial Ataxia continues…

Posted: Published on September 17th, 2013

The Walk to Fight Familial Ataxia is taking place on Saturday, September, 21st in Whitby, Ontario WHITBY, ON, Sept. 16, 2013 /CNW/ - Whitby, Ontario to host The Walk to Fight Familial Ataxia (FA) on September 21st, 2013 from 10 a.m. to 1 p.m. Heydenshore Park, 589 Water Street. Researchers from across Canada to attend, including over 200 participants from all over Ontario. Over the last four years, the Walk to Fight FA has expanded to three other cities across Canada: Montreal (Quebec), Richmond (BC) and Saskatoon (Saskatchewan). The most frequent hereditary ataxia is Friedreich's Ataxia, with an estimated prevalence of 3-4 cases per 100,000 individuals. It is a rare but severe neurodegenerative disease characterized by spinocerebellar degeneration. This often fatal, hereditary degenerative neurological disease, primarily affects balance, coordination and speech. It can also lead to severe scoliosis, heart disease and diabetes. Once diagnosed, most patients find themselves confined to a wheelchair within 10 years. At the moment there is no treatment that can stop or cure FA. However some drugs intended to counteract the effects of this disease are presently on trial. The goal of the Walk is to raise funds for research on FA and to raise public … Continue reading →

Comments Off on The Fight against Familial Ataxia continues…

David Nutt And Howard Marks The Dangers Of Drugs – Video

Posted: Published on September 17th, 2013

David Nutt And Howard Marks The Dangers Of Drugs The Dangers Of Drugs Drug Policy Reform November,2010 Drug laws amount to scientific censorship, says David Nutt David Nutt, and fellow professors Leslie K... By: ITZOUTTHERE … Continue reading →

Posted in Stem Cell Research | Comments Off on David Nutt And Howard Marks The Dangers Of Drugs – Video

Cell research hope for diabetics

Posted: Published on September 17th, 2013

Scientists have come a step closer to developing stem cell treatments for pancreatic diseases such as Type 1 diabetes. A 3D cell culture system was used to mass produce stem cells with the ability to become two kinds of pancreatic cell, including insulin-producing beta cells. The research, conducted on mice, involved cell signalling molecules known as Wnts that are inactive in the adult pancreas. "We have found a way to activate the Wnt pathway to produce an unlimited expansion of pancreatic stem cells isolated from mice," said study leader Dr Hans Clevers, from the Hubrecht Institute in Heidelberg, Germany. "By changing the growth conditions, we can select two different fates for the stem cells and generate large numbers of either hormone-producing beta cells or pancreatic duct cells." Stem cell research holds out great promise for diabetes sufferers who rely on daily insulin injections because they cannot produce insulin. Type 1 diabetes is an auto-immune disease that wipes out the beta cells in the pancreas. However, such research is still at a very early stage. The German scientists, whose findings appear in The EMBO Journal, now plan to extend their technique to human pancreatic cells. Read more here: Cell research hope … Continue reading →

Posted in Stem Cell Research | Comments Off on Cell research hope for diabetics

Mesenchymal stem cell transplantation may heal a mother's childbirth injury

Posted: Published on September 17th, 2013

Public release date: 17-Sep-2013 [ | E-mail | Share ] Contact: Robert Miranda cogcomm@aol.com Cell Transplantation Center of Excellence for Aging and Brain Repair Putnam Valley, NY. (Sept. 17 2013) Vaginal delivery presents the possibility of injury for mothers that can lead to "stress urinary incontinence" (SUI), a condition affecting from four to 35 percent of women who have had babies via vaginal delivery. Many current treatments, such as physiotherapy and surgery, are not very effective. Seeking better methods to alleviate SUI, researchers carried out a study in which female laboratory rats modeled with simulated childbirth injuries received injections of mesenchymal stem cells (MSCs; multipotent cells found in connective tissues that can differentiate into a variety of cell types including: bone, cartilage and fat cells) to see if the cells would home to and help to repair the damaged pelvic organs. The study appears as an early e-publication for the journal Cell Transplantation, and is now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-cog_09636897_ct0957dissaranan. "Stem cell-based therapy has recently gained attention as a promising treatment for SUI," said study co-author Dr. Margot S. Damaser of the Cleveland Clinic's Department of Biomedical Engineering. "Stem cell therapies may be more feasible and less invasive than … Continue reading →

Comments Off on Mesenchymal stem cell transplantation may heal a mother's childbirth injury

Stem cell therapy control sought

Posted: Published on September 16th, 2013

Manila, Philippines More health groups are supporting the stand of the Philippine College of Physicians (PCP) to strengthen government control against the unapproved use of stem cell therapy until conclusive trials had proven its safety and efficacy. The University of the Philippines-National Institutes of Health (UP-NIH) released a statement stressing the importance of clinical trials in proving the efficacy of stem cell treatments. Aside from the NIH, the other medical societies opposing the highly advertised unproven treatments are the Philippine College of Geriatric Medicine, Philippine Society of Allergy, Asthma, and Immunology, Philippine Society of Hematology and Blood Transfusion, Philippine Society of Nephrology, Philippine Neurological Association, Philippine Society of General Surgeons, Philippine College of Surgeons, Philippine Heart Association, Philippine Society of Endocrinology and Metabolism, Philippine Society of Medical Oncology, Diabetes Philippines, Philippine Society of General Internal Medicine, Philippine Society for Vascular Surgery, Philippine Urological Association, Philippine College of Chest Physicians, Philippine Rheumatology Association, Philippine Society of Gastroenterology, Philippine Society for Microbiology and Infectious Diseases, Philippine Academy of Rehabilitation Medicine, Philippine Society of Nuclear Medicine, Academy of Filipino Neurosurgeons, and the Philippine Dermatological Society. The NIH said stem cell therapy, in all its stages collecting, processing, cryopreservation, and delivery of stem cells, … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Stem cell therapy control sought

Page 4,904«..1020..4,9034,9044,9054,906..4,9104,920..»